BCRX

#1723
BioCryst Pharmaceuticals Inc
8.75
+13.49%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
8.75
8.75
Intervallo Annuale
6.00
11.31
Variazione giornaliera
+13.49%
Variazione Mensile
+29.44%
Variazione di 6 mesi
+2.70%
Variazione Annuale
+2.82%
Chiusura Precedente
7.71
Open
8.75
Bid
Ask
Low
8.75
High
8.75
Volume
173
Open full chart

Financials

Overview Estratto Conto Statistics Dividends
Quarterly Annual
  • Market Capitalization 1.84 B
  • Employee 580
  • Founded 1986
  • CEO Jon P. Stonehouse
  • Website www.biocryst.com
  • Headquarter Delaware, United States
  • FIGI BBG000BLYWX6
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
6.45
Price to sales ratio
—
Dividends per share
—
Dividend yield %
—

BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

Notizie